Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX
Lexicon Pharmaceuticals — Q1 2025 Earnings Presentation
20 slides from Lexicon Pharmaceuticals's earnings presentation, May 13, 2025
Slide 1: First Quarter 2025 Earnings Presentation
First Quarter 2025 Earnings Presentation May 13, 2025 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as pr
Slide 3: Business Overview
Business Overview Mike Exton, PhD Director and Chief Executive Officer 3
Slide 4: Significant strategic objectives achieved in 2025
Company Overview Significant strategic objectives achieved in 2025 Pilavapadin (LX9211) Exclusive worldwide PROGRESS readout Reduced debt and licensing agreement identified de-risked dose strengthened financial with Novo Nordisk for to move into Phase 3 position LX9851 trials (10mg) Well-positioned
Slide 5: Pilavapadin has consistently delivered clinically meaningful pain reduction
Pilavapadin Pilavapadin 10 mg has consistently delivered clinically meaningful pain reduction RELIEF Phase 2a ADPS Reduction Time Series PROGRESS Phase 2b ADPS Reduction Time Series 0.0 0.0 LS Mean Change from Baseline LS Mean Change from Baseline -0.5 -0.5 PLACEBO -1.0 -1.0 PLACEBO -1.5 -1.5 PROGRE
Slide 6: Neuropathic pain: A highly prevalent chronic condition with significant unmet need
Pilavapadin Neuropathic pain: A highly prevalent chronic condition with significant unmet need 9M 9M 1 in1 4inpeople in the 4 people U.S. living living with with diabetes Diabetes suffer suffer from fromBy DPNP. DPNP. 2035,By people peopleliving in the with U.S. diabetes living with suffer diabetes
Slide 7: HCM: A significant and underpenetrated market
Sotagliflozin HCM HCM: A significant and underpenetrated market ~1.1 million people in the U.S. have either obstructive or non-obstructive HCM1 70% ~1% Diagnosed Market with oHCM penetration 30% 43% Diagnosed Progressive with nHCM heart failure 1. CVrg Market Strategies. Cardiovascular Resource Grou
Slide 8: Recent understanding of HCM market underscores potential for sotagliflozin
Sotagliflozin HCM Recent understanding of HCM market underscores potential for sotagliflozin Sotagliflozin in HCM Broad proposed indication for both nHCM and oHCM with potential for use alone or in combination Once-daily oral dosing enables broad adoption with no REMS Approved for heart failure with
Slide 9: SONATA Phase 3 study for oHCM and nHCM
Sotagliflozin HCM SONATA Phase 3 study for oHCM and nHCM Global Phase 3 SONATA Trial Enrollment underway Sotagliflozin 400 mg* (N = 250) R 1:1 Only ongoing trial Placebo (N = 250) to evaluate both obstructive and Up to 14 days 4-week non-obstructive HCM 26-week double-blind treatment period screenin
Slide 10: Strategic deal with Novo Nordisk allows LX9851 to "enter the majors"
LX9851 Strategic deal with Novo Nordisk allows LX9851 to "enter the majors" LX9851 First in class, potent, selective, orally bioavailable, investigational small molecule ACSL5 inhibitor Lexicon/LX9851 positioned to benefit from Novo Nordisk size, scale and capabilities Exclusive, worldwide $75 milli
Slide 11: Innovative and flexible partnership approach unlocks long-term value
Partnering Innovative and flexible partnership approach unlocks long-term value by augmenting Lexicon’s capabilities Geographical expansion through Maximizing asset value with Novo’s Unlock value globally and across Viatris’ global capabilities leadership position in obesity multiple indications Pil
Slide 12: Financial Overview
Financial Overview Scott Coiante Chief Financial Officer 12
Slide 13: Q1 2025 Financial Summary
Financials Q1 2025 Financial Summary $ (in millions except per share amounts) As of March 31, As of December Q1 2025 Q1 2024 2025* 31, 2024 Total revenues $1.3 $1.1 Cash, cash equivalents and short-term $194.8 $238.0 R&D $15.3 $14.4 investments SG&A $11.6 $32.1 Total assets $297.7 $298.4 Total opera
Slide 14: 2025 Guidance reflects significantly lower operating expenses
Financials 2025 Guidance reflects significantly lower operating expenses • First quarter included the impact of severance payments related to the restructuring and repositioning announced and accrued in 4Q 2024. YTD 2025 Key Financial Highlights • First quarter did not include cash impact of $45 mil
Slide 15: Summary
Summary Mike Exton, PhD Director and Chief Executive Officer 15
Slide 16: Well-positioned with a portfolio of potential "pipelines in a pill"
Conclusion Well-positioned with a portfolio of potential “pipelines in a pill” Exploring opportunities across multiple therapeutic areas 2025 2026 2027 2028 2029 Pilavapadin (LX9211)* Ph3 Initiation Regulatory Approval Diabetic Peripheral Neuropathic Pain (DPNP) Ph3 Planning / Execution Regulatory A
Slide 17: Lexicon Lead to Succeed strategy
Conclusion Lexicon Lead to Succeed strategy Designed to drive value for all stakeholders Driving value First or only in and growth for therapy or class Lexicon with opportunities for the most LEAD TO impact for S UCC E E D patients S T R AT E G Y Large Leading markets with clinical and significant n
Slide 18: Significant number of planned catalysts through 2025
Conclusion Significant number of planned catalysts through 2025 • Full PROGRESS data anticipated in Q3 Pilavapadin • Diabetic Peripheral Neuropathic • End of Phase 2 meeting planned in Q3 (LX9211) Pain • Data at upcoming medical meetings • Partnership discussions ongoing • EU and LATAM sites enrolli
Slide 19: Q&A
Q&A Mike Exton, PhD Craig Granowitz, MD, PhD Scott Coiante Director and Chief Senior Vice President and Chief Chief Financial Officer Executive Officer Medical Officer 19
Slide 20: Thank You
Thank You pharmaceuticals
Lexicon Pharmaceuticals — Q1 2025 Earnings Presentation on 6ix